CAR T cell therapy for mesothelin-positive solid tumors
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must already be enrolled in the BASECAMP-1 study and have tumor tissue that shows you've lost a specific marker called HLA-A*02
- You have a type of solid tumor (like colorectal, lung, pancreatic, ovarian, or mesothelioma) that tests positive for mesothelin
- You have at least one tumor that is 1 cm or larger on a CT scan
- You've already tried standard treatments for your cancer, but they no longer work or you couldn't handle them
- You feel well enough to be up and active (ECOG score 0 or 1), and your organs are working well
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new kind of immunotherapy called CAR T-cells that are designed to find and attack cancer cells with a protein called mesothelin on their surface. It may help people with mesothelioma or other solid tumors that have not improved with standard treatments.
This trial tests a new treatment called KT032, a type of CAR-T cell therapy, for people with advanced solid tumors (like ovarian cancer, mesothelioma, or colon cancer) that have spread to the belly lining. The treatment is given as an injection and is designed to target a protein called mesothelin on cancer cells. The goal is to see if it's safe and if it can help shrink tumors.
This Phase 1 trial tests a customized immune therapy (CAR-T cells) for advanced cancers that have the proteins mesothelin, GPC3, and/or GUCY2C. It may help your body better recognize and kill cancer cells, but early-phase trials mainly focus on safety and learning how well the treatment works.
This trial tests a new type of immune cell therapy made from your own cells (gamma-delta T cells) that are engineered to find and attack cancers that have GPC3 or mesothelin proteins. It may be an option for people with advanced cancer who have not had gene therapy before and are in generally good health.
This Phase 1 study tests CAR-T cells that are engineered to recognize several cancer “markers” (specific proteins) found on some advanced cancers. It may help by directing the patient’s own immune cells to attack cancer, but eligibility depends on matching the required protein markers.
This trial tests a new type of cell therapy (CAR-T cells) that is designed to find and attack cancer cells showing a protein called mesothelin. It may be an option for people with advanced solid tumors who have exhausted standard treatments.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.